Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Sculpher

Showing results (1-10 of 174) with videos related to

Pageof 18
Sort By:
Pharmacoeconomics|September 5, 2008
NICE's 2008 Methods Guide: sensible consolidation or opportunities missed?Mark Sculpher
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 13, 2010
Reflecting heterogeneity in patient benefits: the role of subgroup analysis with comparative effectivenessMark Sculpher
Pharmacoeconomics|September 5, 2008
Subgroups and heterogeneity in cost-effectiveness analysisMark Sculpher
Pharmacoeconomics|April 21, 2010
Single technology appraisal at the UK National Institute for Health and clinical excellence: a source of evidence and analysis for decision making internationallyMark Sculpher
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 17, 2015
Clinical trials provide essential evidence, but rarely offer a vehicle for cost-effectiveness analysisMark Sculpher
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 26, 2018
ISPOR's Initiative on US Value Assessment Frameworks: Seeking a Role for Health EconomicsMark Sculpher
Nature Medicine|September 11, 2012
Straight talk with... Mark Sculpher. Interview by Kate RaviliousMark Sculpher
Medical Decision Making : an International Journal of the Society for Medical Decision Making|March 23, 2013
Methods development for health technology assessment: is it time to set priorities?Mark Sculpher
BMJ (Clinical Research Ed.)|March 6, 2012
Cost effectiveness of interventions to tackle non-communicable diseasesPaul Revill, Mark Sculpher
Pharmacoeconomics|December 22, 2011
Real economics needs to reflect real decisions: a response to JohnsonMark Sculpher, Karl Claxton
Pageof 18

Showing results (1-10 of 174) with videos related to

Sort By:
Pageof 18
Pharmacoeconomics|September 5, 2008
NICE's 2008 Methods Guide: sensible consolidation or opportunities missed?Mark Sculpher
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 13, 2010
Reflecting heterogeneity in patient benefits: the role of subgroup analysis with comparative effectivenessMark Sculpher
Pharmacoeconomics|September 5, 2008
Subgroups and heterogeneity in cost-effectiveness analysisMark Sculpher
Pharmacoeconomics|April 21, 2010
Single technology appraisal at the UK National Institute for Health and clinical excellence: a source of evidence and analysis for decision making internationallyMark Sculpher
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 17, 2015
Clinical trials provide essential evidence, but rarely offer a vehicle for cost-effectiveness analysisMark Sculpher
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 26, 2018
ISPOR's Initiative on US Value Assessment Frameworks: Seeking a Role for Health EconomicsMark Sculpher
Nature Medicine|September 11, 2012
Straight talk with... Mark Sculpher. Interview by Kate RaviliousMark Sculpher
Medical Decision Making : an International Journal of the Society for Medical Decision Making|March 23, 2013
Methods development for health technology assessment: is it time to set priorities?Mark Sculpher
BMJ (Clinical Research Ed.)|March 6, 2012
Cost effectiveness of interventions to tackle non-communicable diseasesPaul Revill, Mark Sculpher
Pharmacoeconomics|December 22, 2011
Real economics needs to reflect real decisions: a response to JohnsonMark Sculpher, Karl Claxton
Pageof 18